Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome

Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT

(2011) E.A. El-Habr et al.   CLINICAL NEUROPATHOLOGY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

The Ras-ERK pathway: Understanding site-specific signaling provides hope of new anti-tumor therapies

(2010) Fernando Calvo et al.   BIOESSAYS

Higher pAkt Expression Predicts a Significant Worse Prognosis in Glioblastomas

(2010) Yoshiyuki SUZUKI et al.   JOURNAL OF RADIATION RESEARCH

Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats

(2010) C. Renken et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Targeting a Common Collaborator in Cancer Development

(2010) A. P. Myers et al.   Science Translational Medicine

Akt/protein kinase B overexpression as an accurate prognostic marker in adult diffuse astrocytoma

(2009) Tomoo Matsutani et al.   ACTA NEUROCHIRURGICA

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

The PKB/AKT Pathway in Cancer

(2009) Amancio Carnero   CURRENT PHARMACEUTICAL DESIGN